These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38062390)

  • 21. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The
    Hong T; Luo M; Liu Q
    Genet Test Mol Biomarkers; 2020 Apr; 24(4):181-187. PubMed ID: 32202925
    [No Abstract]   [Full Text] [Related]  

  • 23. Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms.
    Sørensen AL; Hasselbalch HC
    Leuk Res; 2016 Feb; 41():27-35. PubMed ID: 26718091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
    Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
    Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Working environment and myeloproliferative neoplasm: A population-based case-control study following a cluster investigation.
    Heavner K; Gross-Davis CA; Frank AL; Newschaffer C; Klotz J; Burstyn I
    Am J Ind Med; 2015 Jun; 58(6):595-604. PubMed ID: 25880722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
    Hultcrantz M; Wilkes SR; Kristinsson SY; Andersson TM; Derolf ÅR; Eloranta S; Samuelsson J; Landgren O; Dickman PW; Lambert PC; Björkholm M
    J Clin Oncol; 2015 Jul; 33(20):2288-95. PubMed ID: 26033810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
    da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Community-acquired infections and their association with myeloid malignancies.
    Titmarsh GJ; McMullin MF; McShane CM; Clarke M; Engels EA; Anderson LA
    Cancer Epidemiol; 2014 Feb; 38(1):56-61. PubMed ID: 24275260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial MPN Predisposition.
    Tashi T; Swierczek S; Prchal JT
    Curr Hematol Malig Rep; 2017 Oct; 12(5):442-447. PubMed ID: 29027642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Exome Sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: A pilot study in patients from the state of Qatar.
    Al-Dewik N; Ben-Omran T; Zayed H; Trujillano D; Kishore S; Rolfs A; Yassin MA
    Gene; 2019 Mar; 689():34-42. PubMed ID: 30553997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
    Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
    Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recruitment strategies and geographic representativeness for patient survey studies in rare diseases: Experience from the living with myeloproliferative neoplasms patient survey.
    Yu J; Paranagama D; Parasuraman S
    PLoS One; 2020; 15(12):e0243562. PubMed ID: 33382745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.
    Ma W; Kantarjian H; Zhang X; Wang X; Zhang Z; Yeh CH; O'Brien S; Giles F; Bruey JM; Albitar M
    PLoS One; 2010 Aug; 5(8):e12165. PubMed ID: 20730051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
    Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
    BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gene mutations in myeloproliferative neoplasms].
    Araki M; Morishita S; Komatsu N
    Rinsho Ketsueki; 2016; 57(12):2526-2534. PubMed ID: 28090022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
    Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
    Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
    Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
    Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Yang C; Zhang Q; Tang X; Wang B; Guan M; Tang G; Wu Z
    Epigenomics; 2022 Apr; 14(7):391-403. PubMed ID: 35259923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
    Haybar H; Khodadi E; Shahjahani M; Saki N
    Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.
    Reuther GW
    Prog Mol Biol Transl Sci; 2016; 144():437-484. PubMed ID: 27865464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.